The European medical cannabis sector is experiencing unprecedented growth, driven by progressive legislation, expanding patient access, and a maturing supply chain, according to a new report.
Findings from The European Cannabis Report: 10th Edition, published today (Tuesday 29 July), reflect a decade of immense change across European cannabis markets — from early medical pilot programs to the emergence of adult-use frameworks in countries like Germany and Malta.
Germany continues to lead the European medical cannabis market, now valued at over €670 million, thanks to the transformative MedCanG law enacted in April 2024. By removing cannabis from the narcotics list and eliminating bureaucratic hurdles, Germany has created Europe’s most open medical cannabis ecosystem. The market is now supported by over 20 telemedicine clinics, a robust import and distribution network, and falling flower prices, further boosting accessibility.
The Czech Republic and Denmark are establishing themselves as rising European exporters. Czech reforms have enabled commercial cultivation and a significant increase in exports – over 1,300 kg of medical cannabis was shipped to Germany in 2024. In Denmark, a decision to make its pilot programme permanent has cemented the country’s role as a major exporter, with over 7 tonnes sent to Germany in 2024 alone.
Poland is now Europe’s fourth-largest market, projected at €72 million in 2025. Recent regulatory improvements, product approvals, and telemedicine adoption spurred rapid growth, although a 2024 ban on online-first consultations has introduced new friction.
In the UK, the medical cannabis market—entirely private—is expected to exceed €300 million in 2025. Over 30 telehealth platforms serve a rapidly expanding patient base, although high treatment prices and a lack of public reimbursement remain key challenges. Domestic production is ramping up, with several UK-based producers now supplying locally cultivated cannabis.
“The UK medical cannabis market is entering a new phase—defined by scale, sophistication, and strong signals of long-term viability,” said Lawrence Purkiss, senior analyst at Prohibition Partners. “As domestic cultivation scales and digital access becomes more embedded, the market is evolving rapidly from niche to mainstream—creating opportunity for global players and local pioneers alike.”
Meanwhile, Italy remains tightly regulated, with state-controlled cultivation and procurement largely restricting market growth. Despite being one of the first movers in Europe, the market remains dominated by a few suppliers, led by Bedrocan.
Across the continent, flowers remain the dominant product format, but oils, extracts, and even vape cartridges are gaining traction—especially in markets like Germany and the UK. Canadian, Portuguese, and Danish producers continue to dominate exports into the region.
As Europe edges closer to harmonised frameworks and broader patient access, the medical cannabis sector is poised for continued acceleration, potentially surpassing €1.5 billion in combined value across leading markets by the end of the decade.
The 10th edition of the European Cannabis Report, long regarded as the go-to European resource for investors, regulators, operators, and policymakers across the global cannabis landscape, is now available to view via Prohibition Partners’ Insights Hub, a dynamic new digital platform unveiled today, that transforms traditional industry reporting into a live, continuously evolving intelligence experience.
“Since 2017, we’ve been charting the evolution of cannabis markets across Europe, we knew it was time for something new that matched the pace, scale, and complexity of what’s happening on the ground,” Prohibition Partners CEO, Stephen Murphy, explained.
“This isn’t just a new edition of our report—it’s a complete reimagining of how we deliver insights and data. The Insights Hub gives businesses, policymakers, and patients real-time access to the data and analysis they need to navigate an industry that is no longer changing year by year, but week by week.”
Prohibition Partners’ Insights Hub is now live and available to access for free. To access and explore, visit: insightshub.prohibitionpartners.com
